Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2026-03-17 00:00:00 ET · period of report 2026-03-13 · accession 0002024096-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-17 | 2026-03-13 | LXEO | Otero Jose Manuel | COO | A - Grant | $2.64 | +5,930 | 131.4K | +5% | +$15.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-13 | A | A | 5,930 | $2.64 | 131,390 | D | — | — | (F1) The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d). (F2) Includes 104,216 restricted stock units. |